#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-5	Brain	_
1-2	6-15	responses	_
1-3	16-18	to	_
1-4	19-28	different	_
1-5	29-34	types	_
1-6	35-37	of	_
1-7	38-46	salience	_
1-8	47-49	in	_
1-9	50-63	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-10	64-69	naïve	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-11	70-75	first	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-12	76-83	episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-13	84-93	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
1-14	94-95	:	_
1-15	96-98	An	_
1-16	99-103	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	104-109	study	_
1-18	110-118	Abnormal	_
1-19	119-127	salience	_
1-20	128-138	processing	_
1-21	139-142	has	_
1-22	143-147	been	_
1-23	148-157	suggested	_
1-24	158-160	to	_
1-25	161-171	contribute	_
1-26	172-174	to	_
1-27	175-178	the	_
1-28	179-188	formation	_
1-29	189-191	of	_
1-30	192-200	positive	_
1-31	201-210	psychotic	_
1-32	211-219	symptoms	_
1-33	220-222	in	_
1-34	223-236	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-35	237-240	and	_
1-36	241-248	related	_
1-37	249-259	conditions	_
1-38	260-261	.	_

2-1	262-270	Previous	_
2-2	271-279	research	_
2-3	280-289	utilising	_
2-4	290-296	reward	_
2-5	297-305	learning	_
2-6	306-308	or	_
2-7	309-321	anticipation	_
2-8	322-331	paradigms	_
2-9	332-335	has	_
2-10	336-348	demonstrated	_
2-11	349-357	cortical	_
2-12	358-361	and	_
2-13	362-373	subcortical	_
2-14	374-387	abnormalities	_
2-15	388-390	in	_
2-16	391-397	people	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-17	398-402	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-18	403-412	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
2-19	413-414	,	_
2-20	415-427	specifically	_
2-21	428-430	in	_
2-22	431-434	the	_
2-23	435-445	prefrontal	_
2-24	446-452	cortex	_
2-25	453-454	,	_
2-26	455-458	the	_
2-27	459-471	dopaminergic	_
2-28	472-480	midbrain	_
2-29	481-484	and	_
2-30	485-488	the	_
2-31	489-497	striatum	_
2-32	498-499	.	_

3-1	500-502	In	_
3-2	503-508	these	_
3-3	509-518	paradigms	_
3-4	519-520	,	_
3-5	521-527	reward	_
3-6	528-538	prediction	_
3-7	539-545	errors	_
3-8	546-555	attribute	_
3-9	556-568	motivational	_
3-10	569-577	salience	_
3-11	578-580	to	_
3-12	581-588	stimuli	_
3-13	589-590	.	_

4-1	591-598	However	_
4-2	599-600	,	_
4-3	601-607	little	_
4-4	608-610	is	_
4-5	611-616	known	_
4-6	617-622	about	_
4-7	623-631	possible	_
4-8	632-645	abnormalities	_
4-9	646-652	across	_
4-10	653-662	different	_
4-11	663-668	forms	_
4-12	669-671	of	_
4-13	672-680	salience	_
4-14	681-691	processing	_
4-15	692-694	in	_
4-16	695-704	psychosis	_
4-17	705-713	patients	_
4-18	714-715	,	_
4-19	716-719	and	_
4-20	720-727	whether	_
4-21	728-731	any	_
4-22	732-736	such	_
4-23	737-750	abnormalities	_
4-24	751-758	involve	_
4-25	759-762	the	_
4-26	763-775	dopaminergic	_
4-27	776-784	midbrain	_
4-28	785-786	.	_

5-1	787-790	The	_
5-2	791-794	aim	_
5-3	795-797	of	_
5-4	798-801	our	_
5-5	802-807	study	_
5-6	808-811	was	_
5-7	812-813	,	_
5-8	814-823	therefore	_
5-9	824-825	,	_
5-10	826-828	to	_
5-11	829-840	investigate	_
5-12	841-849	possible	_
5-13	850-861	alterations	_
5-14	862-864	in	_
5-15	865-874	psychosis	_
5-16	875-877	in	_
5-17	878-884	neural	_
5-18	885-893	activity	_
5-19	894-896	in	_
5-20	897-905	response	_
5-21	906-908	to	_
5-22	909-916	various	_
5-23	917-922	forms	_
5-24	923-925	of	_
5-25	926-934	salience	_
5-26	935-936	:	_
5-27	937-944	novelty	_
5-28	945-946	,	_
5-29	947-955	negative	_
5-30	956-963	emotion	_
5-31	964-965	,	_
5-32	966-976	targetness	_
5-33	977-978	(	_
5-34	979-990	task-driven	_
5-35	991-999	salience	_
5-36	1000-1001	)	_
5-37	1002-1005	and	_
5-38	1006-1023	rareness/deviance	_
5-39	1024-1025	.	_

6-1	1026-1028	We	_
6-2	1029-1036	studied	_
6-3	1037-1039	14	_
6-4	1040-1053	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-5	1054-1059	naïve	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-6	1060-1072	participants	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-7	1073-1077	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-8	1078-1083	first	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-9	1084-1091	episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-10	1092-1101	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-11	1102-1103	,	_
6-12	1104-1107	and	_
6-13	1108-1110	37	_
6-14	1111-1118	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-15	1119-1129	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-16	1130-1131	.	_

7-1	1132-1138	During	_
7-2	1139-1143	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
7-3	1144-1152	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
7-4	1153-1154	,	_
7-5	1155-1167	participants	_
7-6	1168-1177	performed	_
7-7	1178-1179	a	_
7-8	1180-1186	visual	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
7-9	1187-1194	oddball	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
7-10	1195-1199	task	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
7-11	1200-1210	containing	_
7-12	1211-1216	these	_
7-13	1217-1221	four	_
7-14	1222-1227	forms	_
7-15	1228-1230	of	_
7-16	1231-1239	salience	_
7-17	1240-1241	.	_

8-1	1242-1251	Psychosis	_
8-2	1252-1260	patients	_
8-3	1261-1267	showed	_
8-4	1268-1278	abnormally	_
8-5	1279-1286	reduced	_
8-6	1287-1297	signalling	_
8-7	1298-1300	in	_
8-8	1301-1304	the	_
8-9	1305-1315	substantia	_
8-10	1316-1329	nigra/ventral	_
8-11	1330-1339	tegmental	_
8-12	1340-1344	area	_
8-13	1345-1346	(	_
8-14	1347-1353	SN/VTA	_
8-15	1354-1355	)	_
8-16	1356-1359	for	_
8-17	1360-1367	novelty	_
8-18	1368-1369	,	_
8-19	1370-1378	negative	_
8-20	1379-1388	emotional	_
8-21	1389-1397	salience	_
8-22	1398-1401	and	_
8-23	1402-1412	targetness	_
8-24	1413-1414	;	_
8-25	1415-1422	reduced	_
8-26	1423-1431	striatal	_
8-27	1432-1435	and	_
8-28	1436-1445	occipital	_
8-29	1446-1447	(	_
8-30	1448-1455	lingual	_
8-31	1456-1461	gyrus	_
8-32	1462-1463	)	_
8-33	1464-1474	signalling	_
8-34	1475-1477	to	_
8-35	1478-1485	novelty	_
8-36	1486-1489	and	_
8-37	1490-1498	negative	_
8-38	1499-1508	emotional	_
8-39	1509-1517	salience	_
8-40	1518-1519	,	_
8-41	1520-1527	reduced	_
8-42	1528-1538	signalling	_
8-43	1539-1541	in	_
8-44	1542-1545	the	_
8-45	1546-1554	amygdala	_
8-46	1555-1556	,	_
8-47	1557-1565	anterior	_
8-48	1566-1575	cingulate	_
8-49	1576-1582	cortex	_
8-50	1583-1586	and	_
8-51	1587-1601	parahippocamal	_
8-52	1602-1607	gyrus	_
8-53	1608-1610	to	_
8-54	1611-1619	negative	_
8-55	1620-1629	emotional	_
8-56	1630-1638	salience	_
8-57	1639-1640	,	_
8-58	1641-1644	and	_
8-59	1645-1652	reduced	_
8-60	1653-1663	cerebellar	_
8-61	1664-1674	signalling	_
8-62	1675-1677	to	_
8-63	1678-1685	novelty	_
8-64	1686-1689	and	_
8-65	1690-1698	negative	_
8-66	1699-1708	emotional	_
8-67	1709-1717	salience	_
8-68	1718-1719	.	_

9-1	1720-1723	Our	_
9-2	1724-1731	results	_
9-3	1732-1740	indicate	_
9-4	1741-1752	alterations	_
9-5	1753-1755	of	_
9-6	1756-1763	several	_
9-7	1764-1769	forms	_
9-8	1770-1772	of	_
9-9	1773-1781	salience	_
9-10	1782-1792	processing	_
9-11	1793-1795	in	_
9-12	1796-1804	patients	_
9-13	1805-1809	with	_
9-14	1810-1819	psychosis	_
9-15	1820-1822	in	_
9-16	1823-1826	the	_
9-17	1827-1835	midbrain	_
9-18	1836-1842	SN/VTA	_
9-19	1843-1844	,	_
9-20	1845-1849	with	_
9-21	1850-1860	additional	_
9-22	1861-1872	subcortical	_
9-23	1873-1876	and	_
9-24	1877-1885	cortical	_
9-25	1886-1893	regions	_
9-26	1894-1898	also	_
9-27	1899-1906	showing	_
9-28	1907-1918	alterations	_
9-29	1919-1921	in	_
9-30	1922-1930	salience	_
9-31	1931-1941	signalling	_
9-32	1942-1943	,	_
9-33	1944-1947	the	_
9-34	1948-1953	exact	_
9-35	1954-1961	pattern	_
9-36	1962-1964	of	_
9-37	1965-1976	alterations	_
9-38	1977-1986	depending	_
9-39	1987-1989	on	_
9-40	1990-1993	the	_
9-41	1994-1998	form	_
9-42	1999-2001	of	_
9-43	2002-2010	salience	_
9-44	2011-2013	in	_
9-45	2014-2022	question	_
9-46	2023-2024	.	_

10-1	2025-2032	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
10-2	2033-2041	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
10-3	2042-2044	We	_
10-4	2045-2054	recruited	_
10-5	2055-2057	14	_
10-6	2058-2071	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder
10-7	2072-2077	naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-8	2078-2089	individuals	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-9	2090-2094	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-10	2095-2108	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-11	2109-2118	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-12	2119-2122	and	_
10-13	2123-2129	active	_
10-14	2130-2139	psychotic	_
10-15	2140-2148	symptoms	_
10-16	2149-2153	from	_
10-17	2154-2157	the	_
10-18	2158-2167	Cambridge	_
10-19	2168-2169	,	_
10-20	2170-2175	early	_
10-21	2176-2188	intervention	_
10-22	2189-2196	service	_
10-23	2197-2200	for	_
10-24	2201-2210	psychosis	_
10-25	2211-2212	,	_
10-26	2213-2218	CAMEO	_
10-27	2219-2220	.	_

11-1	2221-2226	Other	_
11-2	2227-2236	inclusion	_
11-3	2237-2245	criteria	_
11-4	2246-2250	were	_
11-5	2251-2253	as	_
11-6	2254-2261	follows	_
11-7	2262-2263	:	_
11-8	2264-2267	age	_
11-9	2268-2273	16–35	_
11-10	2274-2279	years	_
11-11	2280-2281	,	_
11-12	2282-2289	meeting	_
11-13	2290-2296	ICD-10	_
11-14	2297-2305	criteria	_
11-15	2306-2309	for	_
11-16	2310-2311	a	_
11-17	2312-2325	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
11-18	2326-2334	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
11-19	2335-2343	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
11-20	2344-2345	(	_
11-21	2346-2352	ICD-10	_
11-22	2353-2354	:	_
11-23	2355-2358	F20	_
11-24	2359-2360	,	_
11-25	2361-2364	F22	_
11-26	2365-2366	,	_
11-27	2367-2370	F23	_
11-28	2371-2372	,	_
11-29	2373-2376	F25	_
11-30	2377-2378	,	_
11-31	2379-2382	F28	_
11-32	2383-2386	and	_
11-33	2387-2390	F29	_
11-34	2391-2392	)	_
11-35	2393-2395	or	_
11-36	2396-2405	affective	_
11-37	2406-2415	psychosis	_
11-38	2416-2417	(	_
11-39	2418-2424	ICD-10	_
11-40	2425-2426	:	_
11-41	2427-2432	F30.2	_
11-42	2433-2434	,	_
11-43	2435-2440	F31.2	_
11-44	2441-2444	and	_
11-45	2445-2450	F32.3	_
11-46	2451-2452	)	_
11-47	2453-2454	.	_

12-1	2455-2458	Age	_
12-2	2459-2460	,	_
12-3	2461-2467	gender	_
12-4	2468-2471	and	_
12-5	2472-2482	handedness	_
12-6	2483-2490	matched	_
12-7	2491-2498	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-8	2499-2509	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-9	2510-2511	(	_
12-10	2512-2513	n	_
12-11	2514-2515	=	_
12-12	2516-2518	37	_
12-13	2519-2520	)	_
12-14	2521-2525	were	_
12-15	2526-2535	recruited	_
12-16	2536-2538	as	_
12-17	2539-2546	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-18	2547-2555	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-19	2556-2557	.	_

13-1	2558-2560	We	_
13-2	2561-2570	recruited	_
13-3	2571-2572	a	_
13-4	2573-2579	higher	_
13-5	2580-2586	number	_
13-6	2587-2589	of	_
13-7	2590-2598	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-8	2599-2603	than	_
13-9	2604-2612	patients	_
13-10	2613-2615	in	_
13-11	2616-2621	order	_
13-12	2622-2624	to	_
13-13	2625-2632	improve	_
13-14	2633-2644	statistical	_
13-15	2645-2650	power	_
13-16	2651-2652	,	_
13-17	2653-2658	given	_
13-18	2659-2662	the	_
13-19	2663-2673	challenges	_
13-20	2674-2676	in	_
13-21	2677-2687	recruiting	_
13-22	2688-2701	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-23	2702-2707	naïve	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-24	2708-2719	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-25	2720-2724	with	_
13-26	2725-2731	active	_
13-27	2732-2741	psychotic	_
13-28	2742-2750	symptoms	_
13-29	2751-2752	(	_
13-30	2753-2756	yet	_
13-31	2757-2762	still	_
13-32	2763-2767	well	_
13-33	2768-2774	enough	_
13-34	2775-2777	to	_
13-35	2778-2786	tolerate	_
13-36	2787-2790	the	_
13-37	2791-2794	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
13-38	2795-2804	procedure	_
13-39	2805-2806	)	_
13-40	2807-2809	in	_
13-41	2810-2815	their	_
13-42	2816-2821	first	_
13-43	2822-2829	episode	_
13-44	2830-2832	of	_
13-45	2833-2840	illness	_
13-46	2841-2842	.	_

14-1	2843-2854	Demographic	_
14-2	2855-2858	and	_
14-3	2859-2867	clinical	_
14-4	2868-2883	characteristics	_
14-5	2884-2886	of	_
14-6	2887-2892	those	_
14-7	2893-2905	participants	_
14-8	2906-2914	included	_
14-9	2915-2917	in	_
14-10	2918-2921	the	_
14-11	2922-2927	final	_
14-12	2928-2936	analysis	_
14-13	2937-2940	are	_
14-14	2941-2950	presented	_
14-15	2951-2953	in	_
14-16	2954-2960	Tables	_
14-17	2961-2962	1	_
14-18	2963-2966	and	_
14-19	2967-2968	2	_
14-20	2969-2970	.	_

15-1	2971-2975	None	_
15-2	2976-2978	of	_
15-3	2979-2982	the	_
15-4	2983-2990	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-5	2991-3001	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-6	3002-3010	reported	_
15-7	3011-3014	any	_
15-8	3015-3023	personal	_
15-9	3024-3026	or	_
15-10	3027-3033	family	_
15-11	3034-3041	history	_
15-12	3042-3044	of	_
15-13	3045-3051	severe	_
15-14	3052-3064	neurological	_
15-15	3065-3066	,	_
15-16	3067-3078	psychiatric	_
15-17	3079-3081	or	_
15-18	3082-3089	medical	_
15-19	3090-3099	disorders	_
15-20	3100-3101	.	_

16-1	3102-3105	All	_
16-2	3106-3118	participants	_
16-3	3119-3122	had	_
16-4	3123-3129	normal	_
16-5	3130-3132	or	_
16-6	3133-3152	corrected-to-normal	_
16-7	3153-3159	vision	_
16-8	3160-3161	,	_
16-9	3162-3165	and	_
16-10	3166-3169	had	_
16-11	3170-3172	no	_
16-12	3173-3190	contraindications	_
16-13	3191-3193	to	_
16-14	3194-3197	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
16-15	3198-3206	scanning	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
16-16	3207-3208	.	_

17-1	3209-3211	At	_
17-2	3212-3215	the	_
17-3	3216-3220	time	_
17-4	3221-3223	of	_
17-5	3224-3227	the	_
17-6	3228-3233	study	_
17-7	3234-3235	,	_
17-8	3236-3240	none	_
17-9	3241-3243	of	_
17-10	3244-3247	the	_
17-11	3248-3260	participants	_
17-12	3261-3265	were	_
17-13	3266-3272	taking	_
17-14	3273-3286	antipsychotic	_
17-15	3287-3297	medication	_
17-16	3298-3300	or	_
17-17	3301-3304	had	_
17-18	3305-3309	drug	_
17-19	3310-3312	or	_
17-20	3313-3320	alcohol	_
17-21	3321-3331	dependence	_
17-22	3332-3333	.	_

18-1	3334-3340	Before	_
18-2	3341-3349	scanning	_
18-3	3350-3351	,	_
18-4	3352-3356	each	_
18-5	3357-3359	of	_
18-6	3360-3363	the	_
18-7	3364-3376	participants	_
18-8	3377-3386	underwent	_
18-9	3387-3388	a	_
18-10	3389-3396	general	_
18-11	3397-3406	interview	_
18-12	3407-3410	and	_
18-13	3411-3419	clinical	_
18-14	3420-3430	assessment	_
18-15	3431-3436	using	_
18-16	3437-3440	the	_
18-17	3441-3449	positive	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-18	3450-3453	and	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-19	3454-3462	negative	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-20	3463-3470	symptom	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-21	3471-3476	scale	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-22	3477-3478	(	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-23	3479-3484	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-24	3485-3486	)	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
18-25	3487-3488	,	_
18-26	3489-3492	the	_
18-27	3493-3498	scale	_
18-28	3499-3502	for	_
18-29	3503-3506	the	_
18-30	3507-3517	assessment	_
18-31	3518-3520	of	_
18-32	3521-3529	negative	_
18-33	3530-3538	symptoms	_
18-34	3539-3540	(	_
18-35	3541-3545	SANS	_
18-36	3546-3547	)	_
18-37	3548-3551	and	_
18-38	3552-3555	the	_
18-39	3556-3562	global	_
18-40	3563-3573	assessment	_
18-41	3574-3576	of	_
18-42	3577-3588	functioning	_
18-43	3589-3590	(	_
18-44	3591-3594	GAF	_
18-45	3595-3596	)	_
18-46	3597-3598	.	_

19-1	3599-3602	The	_
19-2	3603-3607	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
19-3	3608-3618	depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
19-4	3619-3628	inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
19-5	3629-3630	(	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
19-6	3631-3634	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
19-7	3635-3636	)	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
19-8	3637-3640	was	_
19-9	3641-3645	used	_
19-10	3646-3648	to	_
19-11	3649-3655	assess	_
19-12	3656-3666	depressive	_
19-13	3667-3675	symptoms	_
19-14	3676-3682	during	_
19-15	3683-3686	the	_
19-16	3687-3691	last	_
19-17	3692-3695	two	_
19-18	3696-3701	weeks	_
19-19	3702-3703	.	_

20-1	3704-3706	IQ	_
20-2	3707-3710	was	_
20-3	3711-3720	estimated	_
20-4	3721-3726	using	_
20-5	3727-3730	the	_
20-6	3731-3738	culture	_
20-7	3739-3743	fair	_
20-8	3744-3756	intelligence	_
20-9	3757-3761	test	_
20-10	3762-3763	.	_

21-1	3764-3767	The	_
21-2	3768-3773	study	_
21-3	3774-3777	was	_
21-4	3778-3786	approved	_
21-5	3787-3789	by	_
21-6	3790-3793	the	_
21-7	3794-3808	Cambridgeshire	_
21-8	3809-3810	3	_
21-9	3811-3819	National	_
21-10	3820-3826	Health	_
21-11	3827-3834	Service	_
21-12	3835-3843	research	_
21-13	3844-3850	ethics	_
21-14	3851-3860	committee	_
21-15	3861-3862	.	_

22-1	3863-3866	All	_
22-2	3867-3879	participants	_
22-3	3880-3888	supplied	_
22-4	3889-3896	written	_
22-5	3897-3905	informed	_
22-6	3906-3913	consent	_
22-7	3914-3919	after	_
22-8	3920-3924	they	_
22-9	3925-3928	had	_
22-10	3929-3933	read	_
22-11	3934-3935	a	_
22-12	3936-3944	complete	_
22-13	3945-3956	description	_
22-14	3957-3959	of	_
22-15	3960-3963	the	_
22-16	3964-3969	study	_
22-17	3970-3971	.	_

23-1	3972-3979	Novelty	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
23-2	3980-3984	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
23-3	3985-3987	We	_
23-4	3988-3992	used	_
23-5	3993-3994	a	_
23-6	3995-4001	visual	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
23-7	4002-4009	oddball	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
23-8	4010-4018	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#AuditoryOddballTask
23-9	4019-4021	in	_
23-10	4022-4027	order	_
23-11	4028-4030	to	_
23-12	4031-4042	investigate	_
23-13	4043-4047	four	_
23-14	4048-4053	types	_
23-15	4054-4056	of	_
23-16	4057-4065	salience	_
23-17	4066-4067	,	_
23-18	4068-4073	which	_
23-19	4074-4078	were	_
23-20	4079-4086	novelty	_
23-21	4087-4088	,	_
23-22	4089-4097	negative	_
23-23	4098-4107	emotional	_
23-24	4108-4116	salience	_
23-25	4117-4118	,	_
23-26	4119-4129	targetness	_
23-27	4130-4133	and	_
23-28	4134-4151	rareness/deviance	_
23-29	4152-4153	.	_

24-1	4154-4166	Participants	_
24-2	4167-4171	were	_
24-3	4172-4181	presented	_
24-4	4182-4186	with	_
24-5	4187-4188	a	_
24-6	4189-4195	series	_
24-7	4196-4198	of	_
24-8	4199-4208	greyscale	_
24-9	4209-4215	images	_
24-10	4216-4218	of	_
24-11	4219-4224	faces	_
24-12	4225-4228	and	_
24-13	4229-4236	outdoor	_
24-14	4237-4243	scenes	_
24-15	4244-4245	.	_

25-1	4246-4250	66.6	_
25-2	4251-4252	%	_
25-3	4253-4255	of	_
25-4	4256-4261	those	_
25-5	4262-4266	were	_
25-6	4267-4271	used	_
25-7	4272-4274	as	_
25-8	4275-4276	‘	_
25-9	4277-4285	standard	_
25-10	4286-4287	’	_
25-11	4288-4294	images	_
25-12	4295-4296	,	_
25-13	4297-4302	which	_
25-14	4303-4307	were	_
25-15	4308-4310	of	_
25-16	4311-4318	neutral	_
25-17	4319-4328	emotional	_
25-18	4329-4336	valence	_
25-19	4337-4338	.	_

26-1	4339-4342	The	_
26-2	4343-4347	four	_
26-3	4348-4353	types	_
26-4	4354-4356	of	_
26-5	4357-4361	rare	_
26-6	4362-4364	or	_
26-7	4365-4377	contextually	_
26-8	4378-4385	deviant	_
26-9	4386-4392	events	_
26-10	4393-4397	were	_
26-11	4398-4406	randomly	_
26-12	4407-4417	intermixed	_
26-13	4418-4422	with	_
26-14	4423-4428	these	_
26-15	4429-4430	;	_
26-16	4431-4435	each	_
26-17	4436-4444	occurred	_
26-18	4445-4449	with	_
26-19	4450-4451	a	_
26-20	4452-4463	probability	_
26-21	4464-4466	of	_
26-22	4467-4470	8.3	_
26-23	4471-4472	%	_
26-24	4473-4474	.	_

27-1	4475-4480	These	_
27-2	4481-4488	deviant	_
27-3	4489-4495	events	_
27-4	4496-4500	were	_
27-5	4501-4502	:	_
27-6	4503-4510	neutral	_
27-7	4511-4518	stimuli	_
27-8	4519-4523	that	_
27-9	4524-4532	required	_
27-10	4533-4534	a	_
27-11	4535-4540	motor	_
27-12	4541-4549	response	_
27-13	4550-4551	(	_
27-14	4552-4553	‘	_
27-15	4554-4560	target	_
27-16	4561-4568	oddball	_
27-17	4569-4570	’	_
27-18	4571-4572	)	_
27-19	4573-4574	;	_
27-20	4575-4582	stimuli	_
27-21	4583-4587	that	_
27-22	4588-4594	evoked	_
27-23	4595-4596	a	_
27-24	4597-4605	negative	_
27-25	4606-4615	emotional	_
27-26	4616-4624	response	_
27-27	4625-4626	(	_
27-28	4627-4628	‘	_
27-29	4629-4638	emotional	_
27-30	4639-4646	oddball	_
27-31	4647-4648	’	_
27-32	4649-4650	,	_
27-33	4651-4656	angry	_
27-34	4657-4661	face	_
27-35	4662-4664	or	_
27-36	4665-4670	image	_
27-37	4671-4673	of	_
27-38	4674-4677	car	_
27-39	4678-4683	crash	_
27-40	4684-4685	)	_
27-41	4686-4687	;	_
27-42	4688-4693	novel	_
27-43	4694-4701	stimuli	_
27-44	4702-4703	(	_
27-45	4704-4705	‘	_
27-46	4706-4711	novel	_
27-47	4712-4719	oddball	_
27-48	4720-4721	’	_
27-49	4722-4723	,	_
27-50	4724-4733	different	_
27-51	4734-4741	neutral	_
27-52	4742-4748	images	_
27-53	4749-4753	that	_
27-54	4754-4760	appear	_
27-55	4761-4765	only	_
27-56	4766-4770	once	_
27-57	4771-4772	)	_
27-58	4773-4774	;	_
27-59	4775-4778	and	_
27-60	4779-4786	neutral	_
27-61	4787-4794	stimuli	_
27-62	4795-4796	(	_
27-63	4797-4798	‘	_
27-64	4799-4806	neutral	_
27-65	4807-4814	oddball	_
27-66	4815-4816	’	_
27-67	4817-4818	,	_
27-68	4819-4826	neutral	_
27-69	4827-4832	image	_
27-70	4833-4835	of	_
27-71	4836-4840	face	_
27-72	4841-4843	or	_
27-73	4844-4849	scene	_
27-74	4850-4851	)	_
27-75	4852-4853	(	_
27-76	4854-4857	Fig	_
27-77	4858-4859	.	_

28-1	4860-4861	1	_
28-2	4862-4863	)	_
28-3	4864-4865	.	_

29-1	4866-4869	All	_
29-2	4870-4882	participants	_
29-3	4883-4892	completed	_
29-4	4893-4897	four	_
29-5	4898-4904	blocks	_
29-6	4905-4909	with	_
29-7	4910-4912	60	_
29-8	4913-4919	trials	_
29-9	4920-4924	each	_
29-10	4925-4926	,	_
29-11	4927-4936	resulting	_
29-12	4937-4939	in	_
29-13	4940-4941	a	_
29-14	4942-4947	total	_
29-15	4948-4950	of	_
29-16	4951-4954	240	_
29-17	4955-4961	trials	_
29-18	4962-4963	(	_
29-19	4964-4967	160	_
29-20	4968-4976	standard	_
29-21	4977-4983	trials	_
29-22	4984-4985	,	_
29-23	4986-4989	and	_
29-24	4990-4992	20	_
29-25	4993-5000	oddball	_
29-26	5001-5007	trials	_
29-27	5008-5012	each	_
29-28	5013-5015	of	_
29-29	5016-5022	target	_
29-30	5023-5024	,	_
29-31	5025-5032	neutral	_
29-32	5033-5034	,	_
29-33	5035-5044	emotional	_
29-34	5045-5048	and	_
29-35	5049-5054	novel	_
29-36	5055-5062	stimuli	_
29-37	5063-5064	)	_
29-38	5065-5066	.	_

30-1	5067-5070	The	_
30-2	5071-5075	task	_
30-3	5076-5085	contained	_
30-4	5086-5088	50	_
30-5	5089-5090	%	_
30-6	5091-5096	faces	_
30-7	5097-5100	and	_
30-8	5101-5103	50	_
30-9	5104-5105	%	_
30-10	5106-5113	outdoor	_
30-11	5114-5120	scenes	_
30-12	5121-5122	,	_
30-13	5123-5127	this	_
30-14	5128-5135	allowed	_
30-15	5136-5146	prevention	_
30-16	5147-5149	of	_
30-17	5150-5167	category-specific	_
30-18	5168-5179	habituation	_
30-19	5180-5181	.	_

31-1	5182-5187	These	_
31-2	5188-5198	categories	_
31-3	5199-5203	were	_
31-4	5204-5210	chosen	_
31-5	5211-5218	instead	_
31-6	5219-5221	of	_
31-7	5222-5230	abstract	_
31-8	5231-5237	images	_
31-9	5238-5240	to	_
31-10	5241-5245	make	_
31-11	5246-5254	stimulus	_
31-12	5255-5266	exploration	_
31-13	5267-5279	biologically	_
31-14	5280-5288	relevant	_
31-15	5289-5290	.	_

32-1	5291-5303	Participants	_
32-2	5304-5308	were	_
32-3	5309-5319	introduced	_
32-4	5320-5322	to	_
32-5	5323-5326	the	_
32-6	5327-5333	target	_
32-7	5334-5342	stimulus	_
32-8	5343-5348	prior	_
32-9	5349-5351	to	_
32-10	5352-5355	the	_
32-11	5356-5368	experimental	_
32-12	5369-5376	session	_
32-13	5377-5380	for	_
32-14	5381-5384	4.5	_
32-15	5385-5386	s	_
32-16	5387-5388	,	_
32-17	5389-5392	and	_
32-18	5393-5397	they	_
32-19	5398-5402	were	_
32-20	5403-5411	required	_
32-21	5412-5414	to	_
32-22	5415-5419	make	_
32-23	5420-5421	a	_
32-24	5422-5428	simple	_
32-25	5429-5435	button	_
32-26	5436-5441	press	_
32-27	5442-5446	with	_
32-28	5447-5452	their	_
32-29	5453-5458	right	_
32-30	5459-5464	index	_
32-31	5465-5471	finger	_
32-32	5472-5474	in	_
32-33	5475-5483	response	_
32-34	5484-5486	to	_
32-35	5487-5491	each	_
32-36	5492-5494	of	_
32-37	5495-5498	its	_
32-38	5499-5509	subsequent	_
32-39	5510-5521	appearances	_
32-40	5522-5528	during	_
32-41	5529-5532	the	_
32-42	5533-5543	experiment	_
32-43	5544-5550	within	_
32-44	5551-5554	the	_
32-45	5555-5567	fMRI-scanner	_
32-46	5568-5569	.	_

33-1	5570-5572	No	_
33-2	5573-5578	motor	_
33-3	5579-5588	responses	_
33-4	5589-5593	were	_
33-5	5594-5604	associated	_
33-6	5605-5609	with	_
33-7	5610-5613	any	_
33-8	5614-5616	of	_
33-9	5617-5620	the	_
33-10	5621-5626	other	_
33-11	5627-5635	stimulus	_
33-12	5636-5641	types	_
33-13	5642-5643	.	_

34-1	5644-5650	During	_
34-2	5651-5654	the	_
34-3	5655-5670	fMRI-experiment	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
34-4	5671-5672	,	_
34-5	5673-5676	the	_
34-6	5677-5685	pictures	_
34-7	5686-5690	were	_
34-8	5691-5700	presented	_
34-9	5701-5704	for	_
34-10	5705-5708	500	_
34-11	5709-5711	ms	_
34-12	5712-5720	followed	_
34-13	5721-5723	by	_
34-14	5724-5725	a	_
34-15	5726-5731	white	_
34-16	5732-5740	fixation	_
34-17	5741-5746	cross	_
34-18	5747-5749	on	_
34-19	5750-5751	a	_
34-20	5752-5756	grey	_
34-21	5757-5767	background	_
34-22	5768-5769	(	_
34-23	5770-5774	grey	_
34-24	5775-5780	value	_
34-25	5781-5782	=	_
34-26	5783-5786	127	_
34-27	5787-5788	)	_
34-28	5789-5794	using	_
34-29	5795-5797	an	_
34-30	5798-5812	inter-stimulus	_
34-31	5813-5821	interval	_
34-32	5822-5823	(	_
34-33	5824-5827	ISI	_
34-34	5828-5829	)	_
34-35	5830-5832	of	_
34-36	5833-5836	2.7	_
34-37	5837-5839	s.	_
34-38	5840-5843	ISI	_
34-39	5844-5847	was	_
34-40	5848-5856	jittered	_
34-41	5857-5861	with	_
34-42	5862-5866	±300	_
34-43	5867-5869	ms	_
34-44	5870-5871	(	_
34-45	5872-5881	uniformly	_
34-46	5882-5893	distributed	_
34-47	5894-5895	)	_
34-48	5896-5897	.	_

35-1	5898-5901	The	_
35-2	5902-5907	order	_
35-3	5908-5910	of	_
35-4	5911-5918	stimuli	_
35-5	5919-5922	was	_
35-6	5923-5932	optimised	_
35-7	5933-5936	for	_
35-8	5937-5947	efficiency	_
35-9	5948-5952	with	_
35-10	5953-5959	regard	_
35-11	5960-5962	to	_
35-12	5963-5973	estimating	_
35-13	5974-5990	stimulus-related	_
35-14	5991-6003	haemodynamic	_
35-15	6004-6013	responses	_
35-16	6014-6015	.	_

36-1	6016-6019	All	_
36-2	6020-6022	of	_
36-3	6023-6026	the	_
36-4	6027-6034	stimuli	_
36-5	6035-6039	were	_
36-6	6040-6045	taken	_
36-7	6046-6050	from	_
36-8	6051-6058	Bunzeck	_
36-9	6059-6062	and	_
36-10	6063-6068	Düzel	_
36-11	6069-6070	.	_

37-1	6071-6074	The	_
37-2	6075-6080	scalp	_
37-3	6081-6085	hair	_
37-4	6086-6089	and	_
37-5	6090-6094	ears	_
37-6	6095-6097	of	_
37-7	6098-6103	faces	_
37-8	6104-6108	were	_
37-9	6109-6116	removed	_
37-10	6117-6129	artificially	_
37-11	6130-6131	;	_
37-12	6132-6135	the	_
37-13	6136-6143	outdoor	_
37-14	6144-6150	scenes	_
37-15	6151-6154	did	_
37-16	6155-6158	not	_
37-17	6159-6166	include	_
37-18	6167-6172	faces	_
37-19	6173-6174	.	_

38-1	6175-6178	All	_
38-2	6179-6187	pictures	_
38-3	6188-6192	were	_
38-4	6193-6197	grey	_
38-5	6198-6204	scaled	_
38-6	6205-6208	and	_
38-7	6209-6219	normalised	_
38-8	6220-6222	to	_
38-9	6223-6224	a	_
38-10	6225-6229	mean	_
38-11	6230-6234	grey	_
38-12	6235-6240	value	_
38-13	6241-6243	of	_
38-14	6244-6247	127	_
38-15	6248-6249	(	_
38-16	6250-6252	SD	_
38-17	6253-6255	75	_
38-18	6256-6257	)	_
38-19	6258-6259	.	_

39-1	6260-6263	The	_
39-2	6264-6272	pictures	_
39-3	6273-6277	were	_
39-4	6278-6287	projected	_
39-5	6288-6290	on	_
39-6	6291-6293	to	_
39-7	6294-6297	the	_
39-8	6298-6304	centre	_
39-9	6305-6307	of	_
39-10	6308-6309	a	_
39-11	6310-6316	screen	_
39-12	6317-6318	,	_
39-13	6319-6322	and	_
39-14	6323-6326	the	_
39-15	6327-6339	participants	_
39-16	6340-6347	watched	_
39-17	6348-6352	them	_
39-18	6353-6360	through	_
39-19	6361-6362	a	_
39-20	6363-6369	mirror	_
39-21	6370-6377	mounted	_
39-22	6378-6380	on	_
39-23	6381-6384	the	_
39-24	6385-6389	head	_
39-25	6390-6394	coil	_
39-26	6395-6396	,	_
39-27	6397-6407	subtending	_
39-28	6408-6409	a	_
39-29	6410-6416	visual	_
39-30	6417-6422	angle	_
39-31	6423-6425	of	_
39-32	6426-6431	about	_
39-33	6432-6434	8°	_
39-34	6435-6436	.	_

40-1	6437-6440	The	_
40-2	6441-6449	negative	_
40-3	6450-6459	emotional	_
40-4	6460-6465	scene	_
40-5	6466-6474	depicted	_
40-6	6475-6476	a	_
40-7	6477-6487	negatively	_
40-8	6488-6493	rated	_
40-9	6494-6497	car	_
40-10	6498-6506	accident	_
40-11	6507-6508	(	_
40-12	6509-6516	without	_
40-13	6517-6520	any	_
40-14	6521-6527	people	_
40-15	6528-6529	)	_
40-16	6530-6531	.	_

41-1	6532-6535	The	_
41-2	6536-6544	contrast	_
41-3	6545-6552	between	_
41-4	6553-6560	stimuli	_
41-5	6561-6568	allowed	_
41-6	6569-6571	us	_
41-7	6572-6574	to	_
41-8	6575-6582	examine	_
41-9	6583-6588	brain	_
41-10	6589-6598	responses	_
41-11	6599-6601	to	_
41-12	6602-6605	the	_
41-13	6606-6610	pure	_
41-14	6611-6619	stimulus	_
41-15	6620-6627	novelty	_
41-16	6628-6629	(	_
41-17	6630-6631	‘	_
41-18	6632-6637	novel	_
41-19	6638-6639	’	_
41-20	6640-6643	vs.	_
41-21	6644-6645	‘	_
41-22	6646-6653	neutral	_
41-23	6654-6655	’	_
41-24	6656-6657	)	_
41-25	6658-6659	,	_
41-26	6660-6670	targetness	_
41-27	6671-6672	(	_
41-28	6673-6674	‘	_
41-29	6675-6681	target	_
41-30	6682-6683	’	_
41-31	6684-6687	vs.	_
41-32	6688-6689	‘	_
41-33	6690-6697	neutral	_
41-34	6698-6699	’	_
41-35	6700-6701	)	_
41-36	6702-6703	,	_
41-37	6704-6712	negative	_
41-38	6713-6722	emotional	_
41-39	6723-6730	valence	_
41-40	6731-6732	(	_
41-41	6733-6734	‘	_
41-42	6735-6744	emotional	_
41-43	6745-6746	’	_
41-44	6747-6750	vs.	_
41-45	6751-6752	‘	_
41-46	6753-6760	neutral	_
41-47	6761-6762	’	_
41-48	6763-6764	)	_
41-49	6765-6768	and	_
41-50	6769-6786	rareness/deviance	_
41-51	6787-6790	per	_
41-52	6791-6793	se	_
41-53	6794-6795	(	_
41-54	6796-6797	‘	_
41-55	6798-6805	neutral	_
41-56	6806-6807	’	_
41-57	6808-6811	vs.	_
41-58	6812-6813	‘	_
41-59	6814-6822	standard	_
41-60	6823-6824	’	_
41-61	6825-6826	)	_
41-62	6827-6828	(	_
41-63	6829-6832	Fig	_
41-64	6833-6834	.	_

42-1	6835-6836	1	_
42-2	6837-6838	)	_
42-3	6839-6840	.	_

43-1	6841-6843	By	_
43-2	6844-6855	contrasting	_
43-3	6856-6859	the	_
43-4	6860-6868	specific	_
43-5	6869-6876	salient	_
43-6	6877-6884	oddball	_
43-7	6885-6891	events	_
43-8	6892-6896	with	_
43-9	6897-6900	the	_
43-10	6901-6908	neutral	_
43-11	6909-6916	oddball	_
43-12	6917-6923	events	_
43-13	6924-6925	,	_
43-14	6926-6929	and	_
43-15	6930-6939	including	_
43-16	6940-6941	a	_
43-17	6942-6950	separate	_
43-18	6951-6952	,	_
43-19	6953-6963	additional	_
43-20	6964-6965	,	_
43-21	6966-6967	“	_
43-22	6968-6985	rareness/deviance	_
43-23	6986-6987	”	_
43-24	6988-6996	contrast	_
43-25	6997-6998	(	_
43-26	6999-7003	that	_
43-27	7004-7015	corresponds	_
43-28	7016-7018	to	_
43-29	7019-7020	a	_
43-30	7021-7030	classical	_
43-31	7031-7035	pure	_
43-32	7036-7043	oddball	_
43-33	7044-7050	effect	_
43-34	7051-7052	)	_
43-35	7053-7054	,	_
43-36	7055-7057	we	_
43-37	7058-7061	can	_
43-38	7062-7075	differentiate	_
43-39	7076-7086	activation	_
43-40	7087-7089	to	_
43-41	7090-7093	the	_
43-42	7094-7101	various	_
43-43	7102-7107	forms	_
43-44	7108-7110	of	_
43-45	7111-7119	salience	_
43-46	7120-7125	under	_
43-47	7126-7131	study	_
43-48	7132-7133	.	_

44-1	7134-7146	Irrespective	_
44-2	7147-7149	of	_
44-3	7150-7157	whether	_
44-4	7158-7170	participants	_
44-5	7171-7175	were	_
44-6	7176-7180	left	_
44-7	7181-7183	or	_
44-8	7184-7189	right	_
44-9	7190-7196	handed	_
44-10	7197-7198	,	_
44-11	7199-7203	they	_
44-12	7204-7208	used	_
44-13	7209-7214	their	_
44-14	7215-7220	right	_
44-15	7221-7225	hand	_
44-16	7226-7228	to	_
44-17	7229-7234	press	_
44-18	7235-7238	the	_
44-19	7239-7246	buttons	_
44-20	7247-7249	on	_
44-21	7250-7253	the	_
44-22	7254-7260	button	_
44-23	7261-7264	box	_
44-24	7265-7268	for	_
44-25	7269-7272	the	_
44-26	7273-7279	target	_
44-27	7280-7287	picture	_
44-28	7288-7289	.	_

45-1	7290-7299	Behaviour	_
45-2	7300-7308	analysis	_
45-3	7309-7311	An	_
45-4	7312-7320	analysis	_
45-5	7321-7323	of	_
45-6	7324-7332	variance	_
45-7	7333-7334	(	_
45-8	7335-7340	ANOVA	_
45-9	7341-7342	)	_
45-10	7343-7346	was	_
45-11	7347-7351	used	_
45-12	7352-7354	to	_
45-13	7355-7366	investigate	_
45-14	7367-7372	group	_
45-15	7373-7384	differences	_
45-16	7385-7387	in	_
45-17	7388-7396	pressing	_
45-18	7397-7400	the	_
45-19	7401-7408	buttons	_
45-20	7409-7411	in	_
45-21	7412-7420	response	_
45-22	7421-7423	to	_
45-23	7424-7427	the	_
45-24	7428-7434	target	_
45-25	7435-7442	stimuli	_
45-26	7443-7446	and	_
45-27	7447-7456	assessing	_
45-28	7457-7465	reaction	_
45-29	7466-7471	times	_
45-30	7472-7473	.	_

46-1	7474-7477	All	_
46-2	7478-7482	runs	_
46-3	7483-7485	in	_
46-4	7486-7491	which	_
46-5	7492-7504	participants	_
46-6	7505-7511	missed	_
46-7	7512-7516	more	_
46-8	7517-7521	than	_
46-9	7522-7526	five	_
46-10	7527-7533	button	_
46-11	7534-7541	presses	_
46-12	7542-7546	were	_
46-13	7547-7555	excluded	_
46-14	7556-7557	.	_

47-1	7558-7569	Behavioural	_
47-2	7570-7574	data	_
47-3	7575-7579	were	_
47-4	7580-7588	analysed	_
47-5	7589-7594	using	_
47-6	7595-7599	SPSS	_
47-7	7600-7602	21	_
47-8	7603-7604	(	_
47-9	7605-7608	IBM	_
47-10	7609-7614	Corp.	_
47-11	7615-7616	)	_
47-12	7617-7618	.	_

48-1	7619-7623	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
48-2	7624-7628	data	_
48-3	7629-7640	acquisition	_
48-4	7641-7644	and	_
48-5	7645-7653	analysis	_
48-6	7654-7655	A	_
48-7	7656-7663	Siemens	_
48-8	7664-7672	Magnetom	_
48-9	7673-7677	Trio	_
48-10	7678-7681	Tim	_
48-11	7682-7687	syngo	_
48-12	7688-7690	MR	_
48-13	7691-7694	B17	_
48-14	7695-7704	operating	_
48-15	7705-7707	at	_
48-16	7708-7710	3T	_
48-17	7711-7714	was	_
48-18	7715-7719	used	_
48-19	7720-7722	to	_
48-20	7723-7730	collect	_
48-21	7731-7738	imaging	_
48-22	7739-7743	data	_
48-23	7744-7745	.	_

49-1	7746-7759	Gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
49-2	7760-7771	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
49-3	7772-7774	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
49-4	7775-7776	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
49-5	7777-7786	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
49-6	7787-7793	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
49-7	7794-7803	depicting	_
49-8	7804-7808	BOLD	_
49-9	7809-7817	contrast	_
49-10	7818-7822	were	_
49-11	7823-7831	acquired	_
49-12	7832-7836	from	_
49-13	7837-7839	35	_
49-14	7840-7854	non-contiguous	_
49-15	7855-7862	oblique	_
49-16	7863-7868	axial	_
49-17	7869-7874	plane	_
49-18	7875-7881	slices	_
49-19	7882-7884	of	_
49-20	7885-7886	2	_
49-21	7887-7889	mm	_
49-22	7890-7899	thickness	_
49-23	7900-7902	to	_
49-24	7903-7911	minimise	_
49-25	7912-7918	signal	_
49-26	7919-7927	drop-out	_
49-27	7928-7930	in	_
49-28	7931-7934	the	_
49-29	7935-7942	ventral	_
49-30	7943-7950	regions	_
49-31	7951-7952	.	_

50-1	7953-7955	We	_
50-2	7956-7959	did	_
50-3	7960-7963	not	_
50-4	7964-7972	retrieve	_
50-5	7973-7979	images	_
50-6	7980-7982	of	_
50-7	7983-7986	the	_
50-8	7987-7992	whole	_
50-9	7993-7998	brain	_
50-10	7999-8000	;	_
50-11	8001-8004	the	_
50-12	8005-8013	superior	_
50-13	8014-8018	part	_
50-14	8019-8021	of	_
50-15	8022-8025	the	_
50-16	8026-8032	cortex	_
50-17	8033-8036	was	_
50-18	8037-8040	not	_
50-19	8041-8047	imaged	_
50-20	8048-8049	.	_

51-1	8050-8053	The	_
51-2	8054-8064	relaxation	_
51-3	8065-8069	time	_
51-4	8070-8073	was	_
51-5	8074-8078	1620	_
51-6	8079-8081	ms	_
51-7	8082-8083	,	_
51-8	8084-8088	echo	_
51-9	8089-8093	time	_
51-10	8094-8097	was	_
51-11	8098-8100	30	_
51-12	8101-8103	ms	_
51-13	8104-8105	,	_
51-14	8106-8110	flip	_
51-15	8111-8116	angle	_
51-16	8117-8120	was	_
51-17	8121-8124	65°	_
51-18	8125-8126	,	_
51-19	8127-8135	in-plane	_
51-20	8136-8146	resolution	_
51-21	8147-8150	was	_
51-22	8151-8152	3	_
51-23	8153-8154	×	_
51-24	8155-8156	3	_
51-25	8157-8158	×	_
51-26	8159-8160	3	_
51-27	8161-8163	mm	_
51-28	8164-8165	,	_
51-29	8166-8172	matrix	_
51-30	8173-8177	size	_
51-31	8178-8181	was	_
51-32	8182-8184	64	_
51-33	8185-8186	×	_
51-34	8187-8189	64	_
51-35	8190-8191	,	_
51-36	8192-8197	field	_
51-37	8198-8200	of	_
51-38	8201-8205	view	_
51-39	8206-8209	was	_
51-40	8210-8213	192	_
51-41	8214-8215	×	_
51-42	8216-8219	192	_
51-43	8220-8222	mm	_
51-44	8223-8224	,	_
51-45	8225-8228	and	_
51-46	8229-8238	bandwidth	_
51-47	8239-8242	was	_
51-48	8243-8247	2442	_
51-49	8248-8253	Hz/px	_
51-50	8254-8255	.	_

52-1	8256-8257	A	_
52-2	8258-8263	total	_
52-3	8264-8266	of	_
52-4	8267-8270	437	_
52-5	8271-8278	volumes	_
52-6	8279-8282	per	_
52-7	8283-8294	participant	_
52-8	8295-8299	were	_
52-9	8300-8308	acquired	_
52-10	8309-8310	(	_
52-11	8311-8313	35	_
52-12	8314-8320	slices	_
52-13	8321-8325	each	_
52-14	8326-8328	of	_
52-15	8329-8330	2	_
52-16	8331-8333	mm	_
52-17	8334-8343	thickness	_
52-18	8344-8345	,	_
52-19	8346-8357	inter-slice	_
52-20	8358-8361	gap	_
52-21	8362-8363	1	_
52-22	8364-8366	mm	_
52-23	8367-8368	)	_
52-24	8369-8370	.	_

53-1	8371-8374	The	_
53-2	8375-8380	first	_
53-3	8381-8385	five	_
53-4	8386-8393	volumes	_
53-5	8394-8398	were	_
53-6	8399-8408	discarded	_
53-7	8409-8411	to	_
53-8	8412-8417	allow	_
53-9	8418-8421	for	_
53-10	8422-8424	T1	_
53-11	8425-8438	equilibration	_
53-12	8439-8446	effects	_
53-13	8447-8448	.	_

54-1	8449-8452	The	_
54-2	8453-8457	data	_
54-3	8458-8462	were	_
54-4	8463-8471	analysed	_
54-5	8472-8477	using	_
54-6	8478-8481	FSL	_
54-7	8482-8490	software	_
54-8	8491-8492	(	_
54-9	8493-8498	FMRIB	_
54-10	8499-8500	’	_
54-11	8501-8502	s	_
54-12	8503-8511	Software	_
54-13	8512-8519	Library	_
54-14	8520-8521	,	_
54-15	8522-8544	www.fmrib.ox.ac.uk/fsl	_
54-16	8545-8546	)	_
54-17	8547-8554	version	_
54-18	8555-8559	five	_
54-19	8560-8561	.	_

55-1	8562-8574	Participants	_
55-2	8575-8576	’	_
55-3	8577-8581	data	_
55-4	8582-8583	(	_
55-5	8584-8595	first-level	_
55-6	8596-8604	analysis	_
55-7	8605-8606	)	_
55-8	8607-8611	were	_
55-9	8612-8621	processed	_
55-10	8622-8627	using	_
55-11	8628-8631	the	_
55-12	8632-8636	FMRI	_
55-13	8637-8643	Expert	_
55-14	8644-8652	Analysis	_
55-15	8653-8657	Tool	_
55-16	8658-8659	(	_
55-17	8660-8664	FEAT	_
55-18	8665-8666	)	_
55-19	8667-8668	.	_

56-1	8669-8679	Functional	_
56-2	8680-8686	images	_
56-3	8687-8691	were	_
56-4	8692-8701	realigned	_
56-5	8702-8703	,	_
56-6	8704-8710	motion	_
56-7	8711-8720	corrected	_
56-8	8721-8722	(	_
56-9	8723-8730	MCFLIRT	_
56-10	8731-8732	)	_
56-11	8733-8736	and	_
56-12	8737-8746	spatially	_
56-13	8747-8755	smoothed	_
56-14	8756-8760	with	_
56-15	8761-8762	a	_
56-16	8763-8764	4	_
56-17	8765-8767	mm	_
56-18	8768-8778	full-width	_
56-19	8779-8791	half-maximum	_
56-20	8792-8800	Gaussian	_
56-21	8801-8807	kernel	_
56-22	8808-8809	.	_

57-1	8810-8811	A	_
57-2	8812-8821	high-pass	_
57-3	8822-8828	filter	_
57-4	8829-8832	was	_
57-5	8833-8840	applied	_
57-6	8841-8842	(	_
57-7	8843-8846	120	_
57-8	8847-8848	s	_
57-9	8849-8856	cut-off	_
57-10	8857-8858	)	_
57-11	8859-8860	.	_

58-1	8861-8864	All	_
58-2	8865-8871	images	_
58-3	8872-8876	were	_
58-4	8877-8887	registered	_
58-5	8888-8890	to	_
58-6	8891-8894	the	_
58-7	8895-8906	whole-brain	_
58-8	8907-8918	echo-planar	_
58-9	8919-8924	image	_
58-10	8925-8926	(	_
58-11	8927-8930	EPI	_
58-12	8931-8932	)	_
58-13	8933-8934	(	_
58-14	8935-8939	i.e.	_
58-15	8940-8941	,	_
58-16	8942-8952	functional	_
58-17	8953-8958	image	_
58-18	8959-8963	with	_
58-19	8964-8967	the	_
58-20	8968-8979	whole-brain	_
58-21	8980-8985	field	_
58-22	8986-8988	of	_
58-23	8989-8993	view	_
58-24	8994-8995	)	_
58-25	8996-8997	,	_
58-26	8998-9001	and	_
58-27	9002-9006	then	_
58-28	9007-9009	to	_
58-29	9010-9013	the	_
58-30	9014-9024	structural	_
58-31	9025-9030	image	_
58-32	9031-9033	of	_
58-33	9034-9037	the	_
58-34	9038-9051	corresponding	_
58-35	9052-9063	participant	_
58-36	9064-9065	(	_
58-37	9066-9072	MPRAGE	_
58-38	9073-9074	)	_
58-39	9075-9078	and	_
58-40	9079-9089	normalised	_
58-41	9090-9092	to	_
58-42	9093-9095	an	_
58-43	9096-9099	MNI	_
58-44	9100-9108	template	_
58-45	9109-9110	,	_
58-46	9111-9116	using	_
58-47	9117-9123	linear	_
58-48	9124-9136	registration	_
58-49	9137-9141	with	_
58-50	9142-9145	FSL	_
58-51	9146-9151	FLIRT	_
58-52	9152-9153	.	_

59-1	9154-9157	The	_
59-2	9158-9162	five	_
59-3	9163-9174	explanatory	_
59-4	9175-9184	variables	_
59-5	9185-9186	(	_
59-6	9187-9190	EVs	_
59-7	9191-9192	)	_
59-8	9193-9197	that	_
59-9	9198-9200	we	_
59-10	9201-9205	used	_
59-11	9206-9210	were	_
59-12	9211-9214	the	_
59-13	9215-9220	onset	_
59-14	9221-9226	times	_
59-15	9227-9229	of	_
59-16	9230-9233	the	_
59-17	9234-9242	standard	_
59-18	9243-9244	,	_
59-19	9245-9251	target	_
59-20	9252-9253	,	_
59-21	9254-9263	emotional	_
59-22	9264-9265	,	_
59-23	9266-9271	novel	_
59-24	9272-9275	and	_
59-25	9276-9283	neutral	_
59-26	9284-9292	pictures	_
59-27	9293-9294	.	_

60-1	9295-9299	They	_
60-2	9300-9304	were	_
60-3	9305-9313	modelled	_
60-4	9314-9316	as	_
60-5	9317-9318	1	_
60-6	9319-9320	s	_
60-7	9321-9327	events	_
60-8	9328-9331	and	_
60-9	9332-9341	convolved	_
60-10	9342-9346	with	_
60-11	9347-9348	a	_
60-12	9349-9358	canonical	_
60-13	9359-9371	double-gamma	_
60-14	9372-9380	response	_
60-15	9381-9389	function	_
60-16	9390-9391	.	_

61-1	9392-9394	We	_
61-2	9395-9400	added	_
61-3	9401-9402	a	_
61-4	9403-9411	temporal	_
61-5	9412-9422	derivative	_
61-6	9423-9425	to	_
61-7	9426-9429	the	_
61-8	9430-9435	model	_
61-9	9436-9438	to	_
61-10	9439-9443	take	_
61-11	9444-9448	into	_
61-12	9449-9456	account	_
61-13	9457-9465	possible	_
61-14	9466-9476	variations	_
61-15	9477-9479	in	_
61-16	9480-9483	the	_
61-17	9484-9496	haemodynamic	_
61-18	9497-9505	response	_
61-19	9506-9514	function	_
61-20	9515-9516	.	_

62-1	9517-9519	To	_
62-2	9520-9527	capture	_
62-3	9528-9536	residual	_
62-4	9537-9553	movement-related	_
62-5	9554-9563	artefacts	_
62-6	9564-9565	,	_
62-7	9566-9569	six	_
62-8	9570-9580	covariates	_
62-9	9581-9585	were	_
62-10	9586-9590	used	_
62-11	9591-9593	as	_
62-12	9594-9604	regressors	_
62-13	9605-9607	of	_
62-14	9608-9610	no	_
62-15	9611-9619	interest	_
62-16	9620-9621	(	_
62-17	9622-9627	three	_
62-18	9628-9638	rigid-body	_
62-19	9639-9651	translations	_
62-20	9652-9655	and	_
62-21	9656-9661	three	_
62-22	9662-9671	rotations	_
62-23	9672-9681	resulting	_
62-24	9682-9686	from	_
62-25	9687-9698	realignment	_
62-26	9699-9700	)	_
62-27	9701-9702	.	_

63-1	9703-9705	We	_
63-2	9706-9710	used	_
63-3	9711-9715	four	_
63-4	9716-9725	contrasts	_
63-5	9726-9727	:	_
63-6	9728-9742	target–neutral	_
63-7	9743-9744	,	_
63-8	9745-9760	emotion–neutral	_
63-9	9761-9762	,	_
63-10	9763-9776	novel–neutral	_
63-11	9777-9778	,	_
63-12	9779-9782	and	_
63-13	9783-9799	neutral–standard	_
63-14	9800-9801	.	_

64-1	9802-9804	In	_
64-2	9805-9808	the	_
64-3	9809-9810	“	_
64-4	9811-9823	second-level	_
64-5	9824-9825	”	_
64-6	9826-9834	analysis	_
64-7	9835-9836	,	_
64-8	9837-9839	we	_
64-9	9840-9848	averaged	_
64-10	9849-9852	the	_
64-11	9853-9857	four	_
64-12	9858-9864	blocks	_
64-13	9865-9867	of	_
64-14	9868-9871	the	_
64-15	9872-9876	task	_
64-16	9877-9880	for	_
64-17	9881-9885	each	_
64-18	9886-9897	participant	_
64-19	9898-9903	using	_
64-20	9904-9908	FEAT	_
64-21	9909-9913	with	_
64-22	9914-9919	Fixed	_
64-23	9920-9927	Effects	_
64-24	9928-9929	.	_

65-1	9930-9933	For	_
65-2	9934-9944	estimation	_
65-3	9945-9947	of	_
65-4	9948-9953	group	_
65-5	9954-9964	comparison	_
65-6	9965-9966	(	_
65-7	9967-9973	higher	_
65-8	9974-9979	level	_
65-9	9980-9981	,	_
65-10	9982-9984	or	_
65-11	9985-9986	“	_
65-12	9987-9992	third	_
65-13	9993-9998	level	_
65-14	9999-10000	”	_
65-15	10001-10002	)	_
65-16	10003-10013	statistics	_
65-17	10014-10015	,	_
65-18	10016-10018	we	_
65-19	10019-10023	used	_
65-20	10024-10035	permutation	_
65-21	10036-10043	testing	_
65-22	10044-10053	utilising	_
65-23	10054-10057	the	_
65-24	10058-10061	FSL	_
65-25	10062-10071	randomise	_
65-26	10072-10076	tool	_
65-27	10077-10078	,	_
65-28	10079-10083	with	_
65-29	10084-10106	threshold-free-cluster	_
65-30	10107-10118	enhancement	_
65-31	10119-10120	,	_
65-32	10121-10126	which	_
65-33	10127-10135	enhances	_
65-34	10136-10148	cluster-like	_
65-35	10149-10159	structures	_
65-36	10160-10163	but	_
65-37	10164-10171	remains	_
65-38	10172-10185	fundamentally	_
65-39	10186-10187	a	_
65-40	10188-10198	voxel-wise	_
65-41	10199-10210	statistical	_
65-42	10211-10218	testing	_
65-43	10219-10225	method	_
65-44	10226-10227	.	_

66-1	10228-10230	We	_
66-2	10231-10235	used	_
66-3	10236-10240	5000	_
66-4	10241-10253	permutations	_
66-5	10254-10257	and	_
66-6	10258-10260	we	_
66-7	10261-10267	report	_
66-8	10268-10275	results	_
66-9	10276-10278	at	_
66-10	10279-10280	p	_
66-11	10281-10282	=	_
66-12	10283-10287	0.05	_
66-13	10288-10290	or	_
66-14	10291-10295	less	_
66-15	10296-10297	,	_
66-16	10298-10309	family-wise	_
66-17	10310-10315	error	_
66-18	10316-10325	corrected	_
66-19	10326-10329	for	_
66-20	10330-10338	multiple	_
66-21	10339-10350	comparisons	_
66-22	10351-10352	,	_
66-23	10353-10358	using	_
66-24	10359-10362	the	_
66-25	10363-10371	variance	_
66-26	10372-10381	smoothing	_
66-27	10382-10388	option	_
66-28	10389-10390	(	_
66-29	10391-10392	3	_
66-30	10393-10395	mm	_
66-31	10396-10397	)	_
66-32	10398-10400	as	_
66-33	10401-10412	recommended	_
66-34	10413-10416	for	_
66-35	10417-10428	experiments	_
66-36	10429-10433	with	_
66-37	10434-10439	small	_
66-38	10440-10442	to	_
66-39	10443-10449	modest	_
66-40	10450-10456	sample	_
66-41	10457-10462	sizes	_
66-42	10463-10464	,	_
66-43	10465-10467	as	_
66-44	10468-10470	is	_
66-45	10471-10477	common	_
66-46	10478-10480	in	_
66-47	10481-10485	fMRI	_
66-48	10486-10494	research	_
66-49	10495-10496	.	_

67-1	10497-10500	For	_
67-2	10501-10513	illustrative	_
67-3	10514-10522	purposes	_
67-4	10523-10527	only	_
67-5	10528-10529	,	_
67-6	10530-10532	we	_
67-7	10533-10537	then	_
67-8	10538-10547	extracted	_
67-9	10548-10556	contrast	_
67-10	10557-10563	values	_
67-11	10564-10565	(	_
67-12	10566-10574	contrast	_
67-13	10575-10577	of	_
67-14	10578-10587	parameter	_
67-15	10588-10597	estimates	_
67-16	10598-10599	,	_
67-17	10600-10602	or	_
67-18	10603-10608	COPEs	_
67-19	10609-10611	in	_
67-20	10612-10615	FSL	_
67-21	10616-10617	)	_
67-22	10618-10621	for	_
67-23	10622-10626	each	_
67-24	10627-10637	individual	_
67-25	10638-10642	from	_
67-26	10643-10649	voxels	_
67-27	10650-10652	in	_
67-28	10653-10658	which	_
67-29	10659-10670	significant	_
67-30	10671-10676	group	_
67-31	10677-10688	differences	_
67-32	10689-10693	were	_
67-33	10694-10699	found	_
67-34	10700-10701	(	_
67-35	10702-10705	See	_
67-36	10706-10709	bar	_
67-37	10710-10715	chart	_
67-38	10716-10718	in	_
67-39	10719-10723	Figs	_
67-40	10724-10725	.	_

68-1	10726-10728	2b	_
68-2	10729-10732	and	_
68-3	10733-10735	3b	_
68-4	10736-10737	)	_
68-5	10738-10739	.	_

69-1	10740-10743	Our	_
69-2	10744-10748	main	_
69-3	10749-10757	analysis	_
69-4	10758-10761	was	_
69-5	10762-10767	based	_
69-6	10768-10770	on	_
69-7	10771-10772	a	_
69-8	10773-10779	region	_
69-9	10780-10782	of	_
69-10	10783-10791	interest	_
69-11	10792-10793	(	_
69-12	10794-10797	ROI	_
69-13	10798-10799	)	_
69-14	10800-10808	approach	_
69-15	10809-10811	as	_
69-16	10812-10819	follows	_
69-17	10820-10821	.	_

70-1	10822-10825	For	_
70-2	10826-10829	all	_
70-3	10830-10835	types	_
70-4	10836-10838	of	_
70-5	10839-10847	salience	_
70-6	10848-10849	,	_
70-7	10850-10853	our	_
70-8	10854-10861	primary	_
70-9	10862-10872	hypothesis	_
70-10	10873-10881	involved	_
70-11	10882-10885	the	_
70-12	10886-10898	dopaminergic	_
70-13	10899-10905	SN/VTA	_
70-14	10906-10907	,	_
70-15	10908-10913	which	_
70-16	10914-10917	was	_
70-17	10918-10922	used	_
70-18	10923-10925	as	_
70-19	10926-10929	our	_
70-20	10930-10937	primary	_
70-21	10938-10941	ROI	_
70-22	10942-10943	.	_

71-1	10944-10946	It	_
71-2	10947-10950	was	_
71-3	10951-10960	generated	_
71-4	10961-10966	using	_
71-5	10967-10970	the	_
71-6	10971-10984	probabilistic	_
71-7	10985-10990	atlas	_
71-8	10991-10993	of	_
71-9	10994-10999	Murty	_
71-10	11000-11003	and	_
71-11	11004-11014	colleagues	_
71-12	11015-11016	,	_
71-13	11017-11019	in	_
71-14	11020-11025	which	_
71-15	11026-11037	traditional	_
71-16	11038-11048	anatomical	_
71-17	11049-11061	segmentation	_
71-18	11062-11065	was	_
71-19	11066-11076	replicated	_
71-20	11077-11082	using	_
71-21	11083-11084	a	_
71-22	11085-11095	seed-based	_
71-23	11096-11106	functional	_
71-24	11107-11119	connectivity	_
71-25	11120-11128	approach	_
71-26	11129-11132	and	_
71-27	11133-11138	which	_
71-28	11139-11147	provides	_
71-29	11148-11149	a	_
71-30	11150-11154	mask	_
71-31	11155-11159	that	_
71-32	11160-11168	consists	_
71-33	11169-11171	of	_
71-34	11172-11175	the	_
71-35	11176-11178	SN	_
71-36	11179-11182	and	_
71-37	11183-11186	VTA	_
71-38	11187-11188	,	_
71-39	11189-11193	also	_
71-40	11194-11198	used	_
71-41	11199-11201	in	_
71-42	11202-11205	our	_
71-43	11206-11214	previous	_
71-44	11215-11219	work	_
71-45	11220-11221	.	_

72-1	11222-11233	Furthermore	_
72-2	11234-11235	,	_
72-3	11236-11239	for	_
72-4	11240-11244	each	_
72-5	11245-11253	contrast	_
72-6	11254-11256	we	_
72-7	11257-11264	defined	_
72-8	11265-11266	a	_
72-9	11267-11276	secondary	_
72-10	11277-11285	analysis	_
72-11	11286-11287	,	_
72-12	11288-11292	with	_
72-13	11293-11299	either	_
72-14	11300-11303	one	_
72-15	11304-11310	region	_
72-16	11311-11312	,	_
72-17	11313-11315	or	_
72-18	11316-11319	two	_
72-19	11320-11332	non-adjacent	_
72-20	11333-11340	regions	_
72-21	11341-11349	combined	_
72-22	11350-11352	in	_
72-23	11353-11354	a	_
72-24	11355-11361	single	_
72-25	11362-11366	mask	_
72-26	11367-11368	.	_

73-1	11369-11372	For	_
73-2	11373-11380	novelty	_
73-3	11381-11382	,	_
73-4	11383-11385	we	_
73-5	11386-11390	used	_
73-6	11391-11392	a	_
73-7	11393-11402	secondary	_
73-8	11403-11409	region	_
73-9	11410-11412	of	_
73-10	11413-11421	interest	_
73-11	11422-11426	mask	_
73-12	11427-11435	composed	_
73-13	11436-11438	of	_
73-14	11439-11442	the	_
73-15	11443-11451	striatum	_
73-16	11452-11453	(	_
73-17	11454-11459	using	_
73-18	11460-11461	a	_
73-19	11462-11472	hand-drawn	_
73-20	11473-11477	mask	_
73-21	11478-11479	,	_
73-22	11480-11492	encompassing	_
73-23	11493-11497	both	_
73-24	11498-11509	associative	_
73-25	11510-11513	and	_
73-26	11514-11520	limbic	_
73-27	11521-11529	striatum	_
73-28	11530-11531	,	_
73-29	11532-11535	but	_
73-30	11536-11539	not	_
73-31	11540-11552	sensorimotor	_
73-32	11553-11561	striatum	_
73-33	11562-11563	,	_
73-34	11564-11569	based	_
73-35	11570-11572	on	_
73-36	11573-11584	operational	_
73-37	11585-11593	criteria	_
73-38	11594-11595	)	_
73-39	11596-11599	and	_
73-40	11600-11603	the	_
73-41	11604-11609	right	_
73-42	11610-11617	lateral	_
73-43	11618-11625	frontal	_
73-44	11626-11632	cortex	_
73-45	11633-11634	(	_
73-46	11635-11644	utilising	_
73-47	11645-11646	a	_
73-48	11647-11653	sphere	_
73-49	11654-11655	,	_
73-50	11656-11658	10	_
73-51	11659-11661	mm	_
73-52	11662-11663	,	_
73-53	11664-11671	centred	_
73-54	11672-11674	at	_
73-55	11675-11676	x	_
73-56	11677-11678	=	_
73-57	11679-11681	50	_
73-58	11682-11683	,	_
73-59	11684-11685	y	_
73-60	11686-11687	=	_
73-61	11688-11690	30	_
73-62	11691-11692	,	_
73-63	11693-11694	z	_
73-64	11695-11696	=	_
73-65	11697-11699	28	_
73-66	11700-11701	,	_
73-67	11702-11707	based	_
73-68	11708-11710	on	_
73-69	11711-11714	our	_
73-70	11715-11723	previous	_
73-71	11724-11728	work	_
73-72	11729-11730	)	_
73-73	11731-11732	.	_

74-1	11733-11736	For	_
74-2	11737-11745	negative	_
74-3	11746-11755	emotional	_
74-4	11756-11764	salience	_
74-5	11765-11766	,	_
74-6	11767-11770	our	_
74-7	11771-11780	secondary	_
74-8	11781-11787	region	_
74-9	11788-11790	of	_
74-10	11791-11799	interest	_
74-11	11800-11804	mask	_
74-12	11805-11808	was	_
74-13	11809-11817	composed	_
74-14	11818-11820	of	_
74-15	11821-11824	the	_
74-16	11825-11833	striatum	_
74-17	11834-11837	and	_
74-18	11838-11841	the	_
74-19	11842-11850	amygdala	_
74-20	11851-11852	(	_
74-21	11853-11865	anatomically	_
74-22	11866-11873	derived	_
74-23	11874-11878	mask	_
74-24	11879-11884	using	_
74-25	11885-11888	the	_
74-26	11889-11903	Harvard-Oxford	_
74-27	11904-11915	subcortical	_
74-28	11916-11926	structural	_
74-29	11927-11932	atlas	_
74-30	11933-11941	supplied	_
74-31	11942-11946	with	_
74-32	11947-11950	FSL	_
74-33	11951-11952	)	_
74-34	11953-11954	.	_

75-1	11955-11958	For	_
75-2	11959-11969	targetness	_
75-3	11970-11973	and	_
75-4	11974-11982	rareness	_
75-5	11983-11984	,	_
75-6	11985-11987	we	_
75-7	11988-11992	used	_
75-8	11993-11996	the	_
75-9	11997-12005	striatum	_
75-10	12006-12008	as	_
75-11	12009-12012	our	_
75-12	12013-12022	secondary	_
75-13	12023-12026	ROI	_
75-14	12027-12028	.	_

76-1	12029-12038	Parameter	_
76-2	12039-12048	estimates	_
76-3	12049-12052	for	_
76-4	12053-12056	the	_
76-5	12057-12063	events	_
76-6	12064-12068	that	_
76-7	12069-12079	contribute	_
76-8	12080-12082	to	_
76-9	12083-12086	the	_
76-10	12087-12096	contrasts	_
76-11	12097-12099	of	_
76-12	12100-12108	interest	_
76-13	12109-12112	are	_
76-14	12113-12122	presented	_
76-15	12123-12125	in	_
76-16	12126-12129	the	_
76-17	12130-12143	supplementary	_
76-18	12144-12153	materials	_
76-19	12154-12155	(	_
76-20	12156-12169	Supplementary	_
76-21	12170-12177	Figures	_
76-22	12178-12181	5–8	_
76-23	12182-12183	,	_
76-24	12184-12187	and	_
76-25	12188-12190	11	_
76-26	12191-12192	)	_
76-27	12193-12196	for	_
76-28	12197-12200	all	_
76-29	12201-12211	conditions	_
76-30	12212-12214	in	_
76-31	12215-12222	primary	_
76-32	12223-12226	and	_
76-33	12227-12236	secondary	_
76-34	12237-12241	ROIs	_
76-35	12242-12243	.	_

77-1	12244-12247	The	_
77-2	12248-12257	parameter	_
77-3	12258-12267	estimates	_
77-4	12268-12276	indicate	_
77-5	12277-12280	the	_
77-6	12281-12290	potential	_
77-7	12291-12298	drivers	_
77-8	12299-12301	of	_
77-9	12302-12305	the	_
77-10	12306-12310	COPE	_
77-11	12311-12312	(	_
77-12	12313-12321	contrast	_
77-13	12322-12324	of	_
77-14	12325-12334	parameter	_
77-15	12335-12344	estimates	_
77-16	12345-12346	)	_
77-17	12347-12353	effect	_
77-18	12354-12355	.	_

78-1	12356-12359	For	_
78-2	12360-12372	completeness	_
78-3	12373-12374	,	_
78-4	12375-12378	the	_
78-5	12379-12383	same	_
78-6	12384-12392	analysis	_
78-7	12393-12395	as	_
78-8	12396-12405	described	_
78-9	12406-12411	above	_
78-10	12412-12415	has	_
78-11	12416-12420	been	_
78-12	12421-12430	conducted	_
78-13	12431-12433	on	_
78-14	12434-12442	controls	_
78-15	12443-12447	only	_
78-16	12448-12451	and	_
78-17	12452-12454	is	_
78-18	12455-12464	presented	_
78-19	12465-12467	in	_
78-20	12468-12471	the	_
78-21	12472-12483	supplements	_
78-22	12484-12485	(	_
78-23	12486-12499	Supplementary	_
78-24	12500-12506	Figure	_
78-25	12507-12508	9	_
78-26	12509-12510	,	_
78-27	12511-12524	Supplementary	_
78-28	12525-12530	Table	_
78-29	12531-12532	3	_
78-30	12533-12536	and	_
78-31	12537-12538	4	_
78-32	12539-12540	)	_
78-33	12541-12542	.	_

79-1	12543-12551	Movement	_
79-2	12552-12563	differences	_
79-3	12564-12570	during	_
79-4	12571-12575	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
79-5	12576-12580	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
79-6	12581-12583	As	_
79-7	12584-12587	the	_
79-8	12588-12592	task	_
79-9	12593-12596	was	_
79-10	12597-12607	relatively	_
79-11	12608-12612	long	_
79-12	12613-12614	(	_
79-13	12615-12617	46	_
79-14	12618-12621	min	_
79-15	12622-12623	)	_
79-16	12624-12627	and	_
79-17	12628-12634	mostly	_
79-18	12635-12642	passive	_
79-19	12643-12644	(	_
79-20	12645-12651	button	_
79-21	12652-12659	presses	_
79-22	12660-12664	were	_
79-23	12665-12669	only	_
79-24	12670-12678	required	_
79-25	12679-12681	in	_
79-26	12682-12684	20	_
79-27	12685-12688	out	_
79-28	12689-12691	of	_
79-29	12692-12695	the	_
79-30	12696-12701	total	_
79-31	12702-12704	of	_
79-32	12705-12708	240	_
79-33	12709-12715	trials	_
79-34	12716-12717	)	_
79-35	12718-12719	,	_
79-36	12720-12722	we	_
79-37	12723-12728	split	_
79-38	12729-12732	the	_
79-39	12733-12737	task	_
79-40	12738-12742	into	_
79-41	12743-12747	four	_
79-42	12748-12754	blocks	_
79-43	12755-12757	of	_
79-44	12758-12762	11.5	_
79-45	12763-12766	min	_
79-46	12767-12768	.	_

80-1	12769-12774	Still	_
80-2	12775-12779	many	_
80-3	12780-12792	participants	_
80-4	12793-12794	,	_
80-5	12795-12806	independent	_
80-6	12807-12809	of	_
80-7	12810-12815	group	_
80-8	12816-12817	,	_
80-9	12818-12827	exhibited	_
80-10	12828-12837	movements	_
80-11	12838-12839	,	_
80-12	12840-12848	possibly	_
80-13	12849-12852	due	_
80-14	12853-12855	to	_
80-15	12856-12865	tiredness	_
80-16	12866-12867	.	_

81-1	12868-12870	We	_
81-2	12871-12872	,	_
81-3	12873-12882	therefore	_
81-4	12883-12884	,	_
81-5	12885-12893	excluded	_
81-6	12894-12899	those	_
81-7	12900-12906	blocks	_
81-8	12907-12909	in	_
81-9	12910-12915	which	_
81-10	12916-12924	movement	_
81-11	12925-12933	exceeded	_
81-12	12934-12935	3	_
81-13	12936-12938	mm	_
81-14	12939-12941	on	_
81-15	12942-12949	average	_
81-16	12950-12952	or	_
81-17	12953-12955	10	_
81-18	12956-12958	mm	_
81-19	12959-12966	maximum	_
81-20	12967-12968	.	_

82-1	12969-12971	In	_
82-2	12972-12977	total	_
82-3	12978-12979	,	_
82-4	12980-12982	we	_
82-5	12983-12993	identified	_
82-6	12994-12996	14	_
82-7	12997-13001	runs	_
82-8	13002-13006	that	_
82-9	13007-13016	fulfilled	_
82-10	13017-13020	the	_
82-11	13021-13029	movement	_
82-12	13030-13039	exclusion	_
82-13	13040-13049	criterion	_
82-14	13050-13051	.	_

83-1	13052-13054	Of	_
83-2	13055-13060	those	_
83-3	13061-13063	14	_
83-4	13064-13068	runs	_
83-5	13069-13070	,	_
83-6	13071-13073	10	_
83-7	13074-13078	were	_
83-8	13079-13085	either	_
83-9	13086-13090	from	_
83-10	13091-13098	testing	_
83-11	13099-13104	block	_
83-12	13105-13106	3	_
83-13	13107-13109	or	_
83-14	13110-13111	4	_
83-15	13112-13113	,	_
83-16	13114-13115	2	_
83-17	13116-13120	were	_
83-18	13121-13125	from	_
83-19	13126-13133	testing	_
83-20	13134-13139	block	_
83-21	13140-13141	2	_
83-22	13142-13145	and	_
83-23	13146-13147	2	_
83-24	13148-13152	were	_
83-25	13153-13157	from	_
83-26	13158-13165	testing	_
83-27	13166-13171	block	_
83-28	13172-13173	1	_
83-29	13174-13175	.	_

84-1	13176-13188	Additionally	_
84-2	13189-13190	,	_
84-3	13191-13196	three	_
84-4	13197-13201	runs	_
84-5	13202-13205	had	_
84-6	13206-13208	to	_
84-7	13209-13211	be	_
84-8	13212-13223	interrupted	_
84-9	13224-13227	and	_
84-10	13228-13232	were	_
84-11	13233-13242	therefore	_
84-12	13243-13246	not	_
84-13	13247-13256	completed	_
84-14	13257-13259	by	_
84-15	13260-13263	the	_
84-16	13264-13276	participants	_
84-17	13277-13278	.	_

85-1	13279-13281	If	_
85-2	13282-13285	for	_
85-3	13286-13287	a	_
85-4	13288-13294	single	_
85-5	13295-13306	participant	_
85-6	13307-13311	only	_
85-7	13312-13315	one	_
85-8	13316-13318	or	_
85-9	13319-13322	two	_
85-10	13323-13327	runs	_
85-11	13328-13336	remained	_
85-12	13337-13340	for	_
85-13	13341-13349	analysis	_
85-14	13350-13351	,	_
85-15	13352-13354	we	_
85-16	13355-13363	excluded	_
85-17	13364-13368	this	_
85-18	13369-13380	participant	_
85-19	13381-13389	entirely	_
85-20	13390-13391	.	_

86-1	13392-13397	Based	_
86-2	13398-13400	on	_
86-3	13401-13406	these	_
86-4	13407-13417	criterions	_
86-5	13418-13419	,	_
86-6	13420-13422	we	_
86-7	13423-13431	excluded	_
86-8	13432-13437	three	_
86-9	13438-13446	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
86-10	13447-13450	and	_
86-11	13451-13454	one	_
86-12	13455-13464	psychosis	_
86-13	13465-13472	patient	_
86-14	13473-13481	entirely	_
86-15	13482-13483	,	_
86-16	13484-13486	as	_
86-17	13487-13491	well	_
86-18	13492-13494	as	_
86-19	13495-13498	one	_
86-20	13499-13502	run	_
86-21	13503-13505	in	_
86-22	13506-13510	five	_
86-23	13511-13520	psychosis	_
86-24	13521-13529	patients	_
86-25	13530-13533	and	_
86-26	13534-13537	one	_
86-27	13538-13541	run	_
86-28	13542-13544	in	_
86-29	13545-13550	three	_
86-30	13551-13559	controls	_
86-31	13560-13561	.	_

87-1	13562-13564	We	_
87-2	13565-13573	excluded	_
87-3	13574-13579	those	_
87-4	13580-13584	four	_
87-5	13585-13596	individuals	_
87-6	13597-13601	from	_
87-7	13602-13605	all	_
87-8	13606-13614	analyses	_
87-9	13615-13621	within	_
87-10	13622-13626	this	_
87-11	13627-13632	study	_
87-12	13633-13634	.	_

88-1	13635-13637	In	_
88-2	13638-13641	the	_
88-3	13642-13651	remaining	_
88-4	13652-13658	sample	_
88-5	13659-13660	,	_
88-6	13661-13663	we	_
88-7	13664-13672	compared	_
88-8	13673-13676	the	_
88-9	13677-13680	two	_
88-10	13681-13687	groups	_
88-11	13688-13690	in	_
88-12	13691-13694	two	_
88-13	13695-13703	separate	_
88-14	13704-13712	repeated	_
88-15	13713-13720	measure	_
88-16	13721-13727	ANOVAs	_
88-17	13728-13734	across	_
88-18	13735-13738	the	_
88-19	13739-13743	four	_
88-20	13744-13751	testing	_
88-21	13752-13758	blocks	_
88-22	13759-13760	,	_
88-23	13761-13764	one	_
88-24	13765-13768	for	_
88-25	13769-13777	movement	_
88-26	13778-13783	means	_
88-27	13784-13787	and	_
88-28	13788-13791	one	_
88-29	13792-13795	for	_
88-30	13796-13803	maximum	_
88-31	13804-13805	(	_
88-32	13806-13819	Supplementary	_
88-33	13820-13826	Figure	_
88-34	13827-13828	1	_
88-35	13829-13832	and	_
88-36	13833-13834	2	_
88-37	13835-13836	)	_
88-38	13837-13838	.	_

89-1	13839-13841	We	_
89-2	13842-13845	did	_
89-3	13846-13849	not	_
89-4	13850-13854	find	_
89-5	13855-13858	any	_
89-6	13859-13870	significant	_
89-7	13871-13876	group	_
89-8	13877-13878	,	_
89-9	13879-13882	run	_
89-10	13883-13885	or	_
89-11	13886-13898	interactions	_
89-12	13899-13905	effect	_
89-13	13906-13907	,	_
89-14	13908-13915	neither	_
89-15	13916-13919	for	_
89-16	13920-13924	mean	_
89-17	13925-13933	movement	_
89-18	13934-13937	nor	_
89-19	13938-13941	for	_
89-20	13942-13949	maximum	_
89-21	13950-13958	movement	_
89-22	13959-13960	(	_
89-23	13961-13964	all	_
89-24	13965-13966	p	_
89-25	13967-13968	>	_
89-26	13969-13972	0.1	_
89-27	13973-13974	)	_
89-28	13975-13976	.	_

